# Katsura Tsukamoto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5185065/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 37 papers | 1,063 citations | 932766 10 h-index | 433756 31 g-index |
| 40 all docs | 40 docs citations | 40 times ranked | 1426 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Lag Time for New Innovative, First-in-Class, Drug Approval in Japan. Biological and Pharmaceutical Bulletin, 2022, 45, 477-482. | 0.6 | 6 |
| 2 | Impact of expedited programs in the United States, as foreign regulatory factors, on clinical development time in Japan. Journal of Clinical Pharmacy and Therapeutics, 2022, , . | 0.7 | 0 |
| 3 | Clinical development of anticancer drugs can be enhanced using efficacy data of small population clinical trials. Journal of Clinical Pharmacy and Therapeutics, 2022, , . | 0.7 | 0 |
| 4 | Alternative New Mono-scaled Quantitative Benefitâ€“Risk Assessment of Human Papillomavirus Vaccine in Japan. Therapeutic Innovation and Regulatory Science, 2021, 55, 48-55. | 0.8 | 0 |
| 5 | Burden of caring for Alzheimerâ€™s disease or dementia patients in Japan, the US, and EU: results from the National Health and Wellness Survey: a cross-sectional survey. Journal of Medical Economics, 2021, 24, 266-278. | 1.0 | 10 |
| 6 | Humanistic burden among caregivers of patients with Alzheimerâ€™s disease or dementia in Japan: a large-scale cross-sectional survey. Journal of Medical Economics, 2021, 24, 181-192. | 1.0 | 12 |
| 7 | Characteristics of drugs approved in Japan without conducting confirmatory clinical trials. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1582-1590. | 0.7 | 0 |
| 8 | Humanistic and economic burden among caregivers of patients with cancer in Japan. Journal of Medical Economics, 2020, 23, 17-27. | 1.0 | 11 |
| 9 | Factors associated with humanistic burden and indirect cost among patients with cancer in Japan. Journal of Medical Economics, 2020, 23, 1570-1578. | 1.0 | 2 |
| 10 | A population-based study of the humanistic burden among cancer patients in Japan. Journal of Medical Economics, 2020, 23, 429-441. | 1.0 | 2 |
| 11 | The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States. Investigational New Drugs, 2019, 37, 1086-1093. | 1.2 | 18 |
| 12 | Influence of Expedited Programs in the United States on Oncology Drug Development in Japan. Therapeutic Innovation and Regulatory Science, 2019, 53, 199-206. | 0.8 | 6 |
| 13 | Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan. Pharmaceutical Medicine, 2019, 33, 45-52. | 1.0 | 0 |
| 14 | Health Technology Assessment in Japan: A Pharmaceutical Industry Perspective. Therapeutic Innovation and Regulatory Science, 2019, 53, 472-480. | 0.8 | 7 |
| 15 | Future Perspectives for the Treatment of Diabetes: Importance of a Regulatory Framework. Therapeutic Innovation and Regulatory Science, 2019, 53, 535-541. | 0.8 | 2 |
| 16 | Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan. Investigational New Drugs, 2018, 36, 702-708. | 1.2 | 5 |
| 17 | Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan. Clinical Therapeutics, 2018, 40, 284-295. | 1.1 | 6 |
| 18 | New quantitative method for evaluation of motor functions applicable to spinal muscular atrophy. Brain and Development, 2018, 40, 172-180. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Industry Perspective of Pediatric Drug Development in the United States: Involvement of the European Union Countries. Therapeutic Innovation and Regulatory Science, 2018, 52, 49-56. | 0.8 | 4 |
| 20 | Evaluation of the Microbiological Efficacy of a Single 2-Gram Dose of Extended-Release Azithromycin by Population Pharmacokinetics and Simulation in Japanese Patients with Gonococcal Urethritis. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 1.4 | 15 |
| 21 | Delays in New Drug Applications and Associated Factors for Orphan Anticancer Drugs in Japan Compared with the USA. Pharmaceutical Medicine, 2018, 32, 403-412. | 1.0 | 0 |
| 22 | Influence of Breakthrough Therapy Designation in the United States on Oncology Drug Development Timelines in Japan. Pharmaceutical Medicine, 2018, 32, 201-207. | 1.0 | 3 |
| 23 | Development of Novel Pharmaceutical Agents for Alzheimerâ€™s Disease: The Impact of Regulatory Initiatives in Japan and the United States. Clinical Therapeutics, 2015, 37, 1652-1660. | 1.1 | 6 |
| 24 | Embryonic Stem Cell Transplantation Correlates With Endogenous Neurogenin 3 Expression and Pancreas Regeneration in Streptozotocin-injured Mice. Journal of Histochemistry and Cytochemistry, 2009, 57, 1149-1158. | 1.3 | 8 |
| 25 | Glucose Activates a Protein Phosphatase-1-Mediated Signaling Pathway to Enhance Overall Translation in Pancreatic Î²-Cells. Endocrinology, 2007, 148, 609-617. | 1.4 | 75 |
| 26 | Protection of pancreatic Î²-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. Journal of Endocrinology, 2007, 193, 65-74. | 1.2 | 90 |
| 27 | Probe-Independent and Direct Quantification of Insulin mRNA and Growth Hormone mRNA in Enriched Cell Preparations. Diabetes, 2006, 55, 3214-3220. | 0.3 | 52 |
| 28 | Growth Without Growth Hormone Receptor: Estradiol Is a Major Growth Hormone-Independent Regulator of Hepatic IGF-I Synthesis. Journal of Bone and Mineral Research, 2005, 20, 2138-2149. | 3.1 | 76 |
| 29 | Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis. Nature Medicine, 2005, 11, 757-764. | 15.2 | 369 |
| 30 | Redox Control of Exocytosis: Regulatory Role of NADPH, Thioredoxin, and Glutaredoxin. Diabetes, 2005, 54, 2132-2142. | 0.3 | 232 |
| 31 | Gastroprokinetic Effect and Mechanism of SK-896, a New Motilin Analogue, during the Interdigestive Period in Conscious Dogs. Pharmacology, 2001, 63, 95-102. | 0.9 | 7 |
| 32 | Facilitation of Acetylcholine Release by SK-951, a Benzofuran Derivative, via the 5-Hydroxytryptamine4 Receptor in Guinea Pig Stomach. The Japanese Journal of Pharmacology, 2000, 82, 138-143. | 1.2 | 1 |
| 33 | The effect of SK-896 on post-operative ileus in dogs: gastrointestinal motility pattern and transit. European Journal of Pharmacology, 2000, 401, 97-107. | 1.7 | 7 |
| 34 | In vitro Pharmacological Profile of SK-896, a New Human Motilin Analogue. Pharmacology, 2000, 60, 128-135. | 0.9 | 12 |
| 35 | Effects of SK-951, a Benzofuran Derivative, as a Prokinetic Agent in Rats and Dogs.. The Japanese Journal of Pharmacology, 1999, 81, 292-297. | 1.2 | 10 |
| 36 | A 3D-Quantitative Structur-Activity Relationship Study of Benzamide Type Serotonin 5-HT4 Receptor Agonists Based on a Comparative Molecular Field Analysis Model, and the Design and Synthesis of Potent Agonists.. Chemical and Pharmaceutical Bulletin, 1998, 46, 1881-1886. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Serotonin 5-HT4 Receptor Agonistic Activity of the Optical Isomers of (.+-.)-4-Amino-N-(2-(1-azabicyclo(3.3.0)octan-5-yl)ethyl)-5-chloro-2,3-dihydro-2-methylbenzo(b)furan-7-carboxamide. Chemical and Pharmaceutical Bulletin, 1998, 46, 1039-1043. | 0.6 | 6 |